As filed with the U.S. Securities and Exchange Commission on February 9, 2026 Registration No. 333-292260 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Envoy Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 3842 86-1369123 (Name, address, including zip code, and telephone number, including area code, of agent for service) With copies to: Approximate date of commencement ...

As filed with the U.S. Securities and Exchange Commission on February 6, 2026 Registration No. 333-292260 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Envoy Medical, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Delaware 3842 86-1369123 (IRS Employer Identification Number) 4875 White Bear Parkw ...

As filed with the U.S. Securities and Exchange Commission on December 18, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Envoy Medical, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 3842 86-1369123 (IRS Employer Identification Number) 4875 White Bear ...

Core Insights - Envoy Medical will host a fireside chat featuring CEO Brent Lucas and Craig Eggert, the first patient to receive the Acclaim cochlear implant, on December 11, 2025, at 4:30 P.M. ET [1][2] Company Overview - Envoy Medical, listed on NASDAQ as COCH, is a hearing health company focused on innovative technologies for hearing loss, including fully implanted devices like the Esteem active middle ear implant and the investigational Acclaim cochlear implant [3][4] - The Acclaim cochlear implant is designed to address severe to profound sensorineural hearing loss and has received Breakthrough Device Designation from the FDA in 2019 [5] Product Details - The Acclaim cochlear implant utilizes a sensor that leverages the natural anatomy of the ear to capture sound, distinguishing it as a first-of-its-kind hearing device [4] - The Esteem fully implanted active middle ear implant is the only FDA-approved device for adults with moderate to severe sensorineural hearing loss, providing continuous hearing without the need for external components [7]

As filed with the U.S. Securities and Exchange Commission on December 1, 2025. Registration No. 333-290927 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Envoy Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 3842 86-1369123 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (IRS Employer Identification ...

Core Insights - Envoy Medical has secured a new U.S. patent for an innovative cochlear implant system that features a removable earplug sensor and an implanted battery, reinforcing its leadership in next-generation cochlear implant technology [1][2][3] Company Developments - The newly granted patent, titled "Combination Implant System with Removable Earplug Sensor and Implanted Battery," enhances Envoy Medical's intellectual property portfolio and covers systems that include an implantable subsystem with a stimulator and rechargeable energy storage [2][3] - The patent supports the company's long-term innovation strategy and aims to protect future advancements in implanted technologies, not just current devices [3] - Envoy Medical is making positive progress in its pivotal Acclaim® Cochlear Implant clinical trial, which has received Breakthrough Device Designation from the FDA in 2019 [3][4][8] Product Information - The Acclaim Cochlear Implant is designed for individuals with severe to profound sensorineural hearing loss and utilizes a sensor that leverages the natural anatomy of the ear instead of a microphone [7][8] - The Esteem® fully implanted active middle ear implant is another innovative product from Envoy Medical, which has been commercially available in the U.S. since 2010 and allows for continuous hearing without external components [5][9]

Core Insights - Envoy Medical, Inc. reported a quarterly loss of $0.35 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.27, representing an earnings surprise of -29.63% [1] - The company generated revenues of $0.04 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 23.64% [2] - Envoy Medical's shares have declined approximately 50.9% year-to-date, contrasting with the S&P 500's gain of 14.4% [3] Financial Performance - The company has surpassed consensus EPS estimates only once in the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.30 on revenues of $0.06 million, and for the current fiscal year, it is -$1.17 on revenues of $0.2 million [7] Market Outlook - The earnings outlook and estimate revisions trend for Envoy Medical were favorable prior to the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] - The Medical - Instruments industry, to which Envoy Medical belongs, is currently ranked in the top 31% of over 250 Zacks industries, suggesting a positive industry outlook [8]

Core Insights - ClearPoint Neuro, Inc. reported a quarterly loss of $0.21 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.20, marking a year-over-year increase from a loss of $0.18 per share [1] - The company generated revenues of $8.86 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 10.5%, but showing an increase from $8.12 million in the same quarter last year [2] - ClearPoint Neuro's stock has increased by approximately 10.4% since the beginning of the year, underperforming compared to the S&P 500's gain of 15.6% [3] Earnings Outlook - The earnings outlook for ClearPoint Neuro is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.19 on revenues of $10.7 million, and for the current fiscal year at -$0.81 on revenues of $38.3 million [7] - The company's Zacks Rank is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Instruments industry, to which ClearPoint Neuro belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - Avanos Medical reported quarterly earnings of $0.22 per share, exceeding the Zacks Consensus Estimate of $0.16 per share, but down from $0.36 per share a year ago, representing an earnings surprise of +37.50% [1] - The company achieved revenues of $177.8 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 6.88% and up from $170.4 million year-over-year [2] Financial Performance - Over the last four quarters, Avanos Medical has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] - The current consensus EPS estimate for the upcoming quarter is $0.29 on revenues of $176.14 million, and for the current fiscal year, it is $0.92 on revenues of $684.98 million [7] Market Position - Avanos Medical shares have declined approximately 29% since the beginning of the year, contrasting with the S&P 500's gain of 15.1% [3] - The Zacks Industry Rank places the Medical - Instruments sector in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] Future Outlook - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current Zacks Rank for Avanos Medical is 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6]

Core Insights - Delcath Systems, Inc. (DCTH) reported quarterly earnings of $0.02 per share, matching the Zacks Consensus Estimate, and showing improvement from a loss of $0.03 per share a year ago [1] - The company achieved revenues of $20.56 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 0.41% and significantly up from $11.2 million year-over-year [2] - Delcath Systems shares have underperformed, losing about 20.9% since the beginning of the year, while the S&P 500 has gained 16.5% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.02 on revenues of $19.51 million, and for the current fiscal year, it is $0.13 on revenues of $83.93 million [7] - The estimate revisions trend for Delcath Systems was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Instruments industry, to which Delcath Systems belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]